Management of Excessive Daytime Sleepiness

Initial Assessment and Treatment

The American Academy of Sleep Medicine recommends quantifying sleepiness severity using the Epworth Sleepiness Scale before initiating pharmacologic treatment 3, 1
The American Geriatrics Society suggests screening for sleep-disordered breathing, which requires polysomnography if present, before starting treatment 4
The National Comprehensive Cancer Network recommends treating primary sleep disorders first, such as obstructive sleep apnea with CPAP/BiPAP, before adding wake-promoting agents 4
Ensuring adequate sleep opportunity is crucial to exclude simple sleep deprivation as the cause of excessive daytime sleepiness 3, 1

The American Academy of Sleep Medicine strongly recommends modafinil as first-line therapy for excessive daytime sleepiness, with a starting dose of 100 mg once upon awakening, titrated to a typical dose range of 200-400 mg daily 1, 2, 3
Modafinil provides significant improvement in excessive daytime sleepiness, disease severity, and quality of life, according to the American Academy of Sleep Medicine 2

The American Academy of Sleep Medicine strongly recommends sodium oxybate for comprehensive symptom control when both excessive daytime sleepiness and cataplexy are present, administered as a liquid in two divided doses at night 1, 2
Pitolisant is strongly recommended as an alternative first-line agent, providing clinically significant improvements in excessive daytime sleepiness, cataplexy, and disease severity, according to the American Academy of Sleep Medicine 2

Methylphenidate or dextroamphetamine may be used as second-line options, with a starting dose of 2.5-5 mg orally with breakfast, and a second dose at lunch if needed, according to the National Comprehensive Cancer Network 4, 3

The American Geriatrics Society recommends starting at lower doses and titrating more gradually in elderly patients, and avoiding benzodiazepines due to decreased cognitive performance 3, 1, 4
The National Comprehensive Cancer Network suggests caffeine and dextroamphetamine as additional options for palliative care patients, with the last dose of caffeine given no later than 4:00 PM 4

The American Academy of Sleep Medicine recommends using the Epworth Sleepiness Scale at each visit to monitor treatment response, and more frequent follow-up when starting medications or adjusting doses 3, 1, 2
Monitoring for adverse effects of stimulants at each visit is crucial, according to the American Academy of Sleep Medicine 2